Today: 30 June 2026
BellRing Brands stock slides 6% on securities-probe headline as BRBR nears 52-week low
5 January 2026
1 min read

BellRing Brands stock slides 6% on securities-probe headline as BRBR nears 52-week low

New York, January 5, 2026, 14:46 EST — Regular session

  • BRBR down about 6% in afternoon trade, after touching $23.96 intraday
  • Law firm Bleichmar Fonti & Auld said it opened a securities class action investigation
  • Focus shifts to early-February results for an update on demand and margins

Shares of BellRing Brands fell 6.1% to $24.49 in afternoon trading on Monday, after touching an intraday low of $23.96.

The move left the stock within about $2 of its 52-week low and roughly 70% below its 52-week high, extending a steep slide that has kept investors wary of the company’s near-term outlook.

That matters now because BellRing’s next quarterly update is approaching, and the stock is trading near levels that can force investors to reassess risk, especially after the company warned of a soft start to fiscal 2026.

Bleichmar Fonti & Auld LLP said in a Newsfile release that it is investigating BellRing Brands for potential violations of federal securities laws, a step that can precede a shareholder class action lawsuit.

BellRing’s drop outpaced the broader consumer-staples group: the Consumer Staples Select Sector SPDR fund was down about 0.2%, while packaged-food peer Simply Good Foods fell about 2.6% and Post Holdings slid about 2.3%.

BellRing, whose brands include Premier Protein and Dymatize, last set out its fiscal 2026 outlook in November, calling for net sales of $2.41 billion to $2.49 billion and adjusted EBITDA of $425 million to $455 million. Adjusted EBITDA is a profit measure that strips out interest, taxes and certain non-cash or one-time items to better show operating performance.

“We delivered strong results in 2025, with sales up 16%,” CEO Darcy Davenport said at the time, while noting the first quarter reflected “short-term challenges,” including an expected roughly 5% decline in net sales from a year earlier. Bellring

BellRing has also leaned on buybacks to support its stock. The company said its board approved a new $600 million share repurchase authorization over the next two years, replacing an earlier $400 million plan.

Still, the law-firm probe adds another overhang to a stock already sensitive to changes in demand signals and cost pressures, and any further reset in expectations could deepen the slide.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • CELZ Jumps 252% as Creative Medical Technology Drops Equity Offer
    June 30, 2026, 12:50 PM EDT. Shares of Creative Medical Technology Holdings (NASDAQ:CELZ) shot up 252% Tuesday after the company pulled its June 25 S-1 for an equity and warrant deal. CELZ said it had not issued any shares under the canceled filing. Trading was heavy, hitting 146.1 million shares-almost 40 times its 3.7 million shares outstanding. The shelved offer would have meant 3.05 million new shares and warrants for another 6.09 million. CEO Timothy Warbington said they decided not to go ahead with the fundraising plan. Biotech ETFs didn't move much, pointing to a CELZ-specific jump. Still, analysts say cash remains tight, with limited room for rounds of regulatory approvals after December 2027.
Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap
Previous Story

Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap

SpaceX lines up back-to-back Starlink launches from Florida as orbit crowding comes into focus
Next Story

SpaceX lines up back-to-back Starlink launches from Florida as orbit crowding comes into focus

Go toTop